Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness, safety and immunogenicity of chikungunya vaccination in populations at risk of severe or complicated forms: an ambispective study in La Réunion
2025-521307-43-00Phase 4Authorised
- Sponsor
- CHU de La Réunion
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of chikungunya vaccine (live) and CHIKV VLP vaccine in Chikungunya (CHIKV) (2 cohorts), sponsored by CHU de La Réunion. Primary endpoint: Vaccine effectiveness against chikungunya infection. Planned start Apr 2025; status: authorised.
02
Drugs
chikungunya vaccine (live)CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2025-521307-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521307-43-00.